RxDoctor Payments DataLook up a doctor →

Ryan Rich, MD

Ophthalmology · Colorado Springs, CONPI 1992720064

Payments from drug & device makers

$2,086,994in general payments, 2019–2025

Across 156 payments — averaging $13,378 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$1.2M
  • Novartis$623K
  • AstraZeneca$178K
  • Roche TCRC, Inc.$44K
  • Regeneron$40K
  • AbbVie$17K
  • plus $6K from 6 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.67$1,177,880
Novartis16$623,116
AstraZeneca4$178,051
Roche TCRC, Inc.9$44,155
Regeneron34$39,992
AbbVie(2 entities)5$17,404
US Retina LLC10$5,970
Alcon3$231
Genentech USA, Inc.5$136
Apellis Pharmaceuticals, Inc.1$30
Eyepoint US, Inc.1$24
Optos, Inc.1$7

How this compares

$2,086,994 in reported general payments places this provider in the 95th percentile of 262 ophthalmology providers in Colorado.

See all ophthalmology providers in Colorado

Medicare billing

Part B allowed, 2024
$4,227,511
Medicare patients
875
Services billed
66,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →